Dyne Therapeutics Stock Today
| DYN Stock | USD 30.96 0.54 1.71% |
Performance4 of 100
| Odds Of DistressLess than 6
|
Dyne Therapeutics is selling at 30.96 as of the 12th of June 2024; that is -1.71 percent decrease since the beginning of the trading day. The stock's open price was 31.5. Dyne Therapeutics has only a 6 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Dyne Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of March 2024 and ending today, the 12th of June 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of September 2020 | Category Healthcare | Classification Health Care |
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.. The company has 99.46 M outstanding shares of which 9.36 M shares are currently shorted by investors with about 11.88 days to cover. More on Dyne Therapeutics
Moving against Dyne Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Dyne Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Joshua Brumm | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dyne Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dyne Therapeutics' financial leverage. It provides some insight into what part of Dyne Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dyne Therapeutics (DYN) is traded on NASDAQ Exchange in USA. It is located in 1560 Trapelo Road, Waltham, MA, United States, 02451 and employs 143 people. Dyne Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 3.13 B. Dyne Therapeutics runs under Biotechnology sector within Health Care industry. The entity has 99.46 M outstanding shares of which 9.36 M shares are currently shorted by investors with about 11.88 days to cover.
Dyne Therapeutics has about 291.84 M in cash with (188.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64.
Check Dyne Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Dyne Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dyne Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dyne Therapeutics. Please pay attention to any change in the institutional holdings of Dyne Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Dyne Ownership Details
Dyne Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Adage Capital Partners Gp Llc | 2024-03-31 | 2.3 M | |
| Vr Adviser, Llc | 2024-03-31 | 2.2 M | |
| Sofinnova Ventures | 2024-03-31 | 1.9 M | |
| Franklin Resources Inc | 2024-03-31 | 1.8 M | |
| Logos Global Management Lp | 2024-03-31 | 1.7 M | |
| Goldman Sachs Group Inc | 2024-03-31 | 1.7 M | |
| Vivo Capital, Llc | 2024-03-31 | 1.6 M | |
| Artal Group S A | 2024-03-31 | 1.5 M | |
| Geode Capital Management, Llc | 2024-03-31 | 1.3 M | |
| Fcpm Iii Services Bv | 2024-03-31 | 7.8 M | |
| Blackrock Inc | 2024-03-31 | 5.4 M |
Dyne Therapeutics Historical Income Statement
Dyne Stock Against Markets
Dyne Therapeutics Corporate Management
| Romesh Subramanian | CoFounder Advisor | Profile | |
| Richard MBA | Senior Administration | Profile | |
| Oxana Beskrovnaya | Chief Officer | Profile | |
| Daniel Wilson | Senior Legal | Profile | |
| Susanna MBA | Chief Officer | Profile | |
| MS MD | VP Pharmacovigilance | Profile |
Additional Information and Resources on Investing in Dyne Stock
When determining whether Dyne Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.98) | Return On Assets (0.41) | Return On Equity (0.71) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.